Skip to main content
main-content

16-09-2022 | ESMO 2022 | Conference coverage | Video

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC

share
SHARE

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations (2:59).

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.